Q4 2024 EPS Estimates for Cencora, Inc. Raised by Leerink Partnrs (NYSE:COR)

Cencora, Inc. (NYSE:COR) – Analysts at Leerink Partnrs raised their Q4 2024 EPS estimates for Cencora in a research report issued to clients and investors on Thursday, September 5th. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings of $3.24 per share for the quarter, up from their previous forecast of $3.21. The consensus estimate for Cencora’s current full-year earnings is $13.61 per share. Leerink Partnrs also issued estimates for Cencora’s Q1 2025 earnings at $3.43 EPS, Q2 2025 earnings at $4.11 EPS, Q4 2025 earnings at $3.62 EPS, FY2025 earnings at $14.84 EPS, FY2026 earnings at $16.54 EPS and FY2027 earnings at $18.29 EPS.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The business had revenue of $74.20 billion for the quarter, compared to analysts’ expectations of $73.32 billion. During the same period last year, the business earned $2.92 EPS. The business’s revenue was up 10.8% on a year-over-year basis.

COR has been the subject of several other research reports. StockNews.com raised Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. raised their price target on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Wells Fargo & Company raised their price target on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Leerink Partners restated an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a research note on Thursday, June 27th. Finally, Robert W. Baird reduced their price objective on Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research note on Friday, September 6th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $258.13.

Cencora Stock Performance

Shares of NYSE COR opened at $237.53 on Monday. The firm has a 50 day moving average of $232.70 and a 200 day moving average of $233.22. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93. The firm has a market capitalization of $46.81 billion, a price-to-earnings ratio of 25.99, a price-to-earnings-growth ratio of 1.54 and a beta of 0.44. Cencora has a 12-month low of $172.41 and a 12-month high of $247.66.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 9th were issued a dividend of $0.51 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.86%. Cencora’s dividend payout ratio (DPR) is 22.32%.

Insider Transactions at Cencora

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the sale, the insider now directly owns 19,980,000 shares of the company’s stock, valued at approximately $4,806,388,800. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Cencora news, EVP Silvana Battaglia sold 1,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares of the company’s stock, valued at approximately $2,656,970.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the transaction, the insider now directly owns 19,980,000 shares of the company’s stock, valued at $4,806,388,800. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,450,399 shares of company stock valued at $1,070,392,799. 15.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cencora

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. purchased a new position in shares of Cencora during the 4th quarter worth approximately $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Cencora during the 1st quarter worth approximately $2,183,619,000. JPMorgan Chase & Co. purchased a new position in shares of Cencora during the 1st quarter worth approximately $1,199,695,000. Boston Partners purchased a new position in Cencora in the 1st quarter valued at approximately $1,001,269,000. Finally, Capital Research Global Investors purchased a new position in Cencora in the 1st quarter valued at approximately $650,424,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.